Janis M. Taube

73.6k total citations · 13 hit papers
205 papers, 20.7k citations indexed

About

Janis M. Taube is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Janis M. Taube has authored 205 papers receiving a total of 20.7k indexed citations (citations by other indexed papers that have themselves been cited), including 129 papers in Oncology, 52 papers in Immunology and 46 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Janis M. Taube's work include Cancer Immunotherapy and Biomarkers (98 papers), Immunotherapy and Immune Responses (40 papers) and CAR-T cell therapy research (37 papers). Janis M. Taube is often cited by papers focused on Cancer Immunotherapy and Biomarkers (98 papers), Immunotherapy and Immune Responses (40 papers) and CAR-T cell therapy research (37 papers). Janis M. Taube collaborates with scholars based in United States, United Kingdom and Germany. Janis M. Taube's co-authors include Drew M. Pardoll, Suzanne L. Topalian, Robert A. Anders, Haiying Xu, Lieping Chen, Julie R. Brahmer, Tracee L. McMiller, Charles G. Drake, Joel Sunshine and Rajni Sharma and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

Janis M. Taube

196 papers receiving 20.5k citations

Hit Papers

Phase I Study of Single-Agent Anti–Programmed Death-1 (MD... 2010 2026 2015 2020 2010 2016 2014 2012 2014 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
    2010 2.3k citations Julie R. Brahmer, Charles G. Drake et al. Journal of Clinical Oncology profile →
  2. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
    2016 2.0k citations Suzanne L. Topalian, Janis M. Taube et al. profile →
  3. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
    2014 1.9k citations Janis M. Taube, Alison Klein et al. Clinical Cancer Research profile →
  4. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
    2012 1.7k citations Janis M. Taube, Robert A. Anders et al. profile →
  5. The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
    2014 1.1k citations Nicolás J. Llosa, Michael Cruise et al. Cancer Discovery profile →
  6. Neoadjuvant checkpoint blockade for cancer immunotherapy
    2020 664 citations Suzanne L. Topalian, Janis M. Taube et al. profile →
  7. Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
    2015 643 citations Kristin J. Lastwika, Willie Wilson et al. Cancer Research profile →
  8. Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
    2013 602 citations Sofía Lyford-Pike, Shiwen Peng et al. Cancer Research profile →
  9. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
    2017 576 citations Janis M. Taube, Robert A. Anders et al. profile →
  10. PD-1/PD-L1 inhibitors
    2015 421 citations Joel Sunshine, Janis M. Taube profile →
  11. Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade
    2019 405 citations Julie E. Stein, Robert A. Anders et al. profile →
  12. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma
    2016 359 citations Elizabeth D. Thompson, Marianna Zahurak et al. Gut profile →
  13. LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC
    2023 67 citations Janis M. Taube et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Janis M. Taube United States 55 15.5k 7.9k 4.8k 3.6k 2.4k 205 20.7k
Timothy A. Chan United States 77 10.4k 0.7× 4.5k 0.6× 5.5k 1.1× 9.4k 2.6× 2.0k 0.8× 243 22.7k
Sandra Demaria United States 65 14.7k 0.9× 10.6k 1.3× 4.8k 1.0× 3.6k 1.0× 1.5k 0.6× 192 21.7k
Daniel S. Chen United States 29 13.3k 0.9× 8.5k 1.1× 4.6k 1.0× 5.1k 1.4× 1.8k 0.7× 50 20.1k
Sarina A. Piha‐Paul United States 53 9.3k 0.6× 2.9k 0.4× 4.2k 0.9× 4.0k 1.1× 2.5k 1.0× 432 14.7k
Omid Hamid United States 68 21.3k 1.4× 9.8k 1.2× 4.9k 1.0× 8.0k 2.2× 1.5k 0.6× 414 26.3k
Haidong Dong United States 60 13.7k 0.9× 11.4k 1.4× 3.5k 0.7× 3.4k 0.9× 1.6k 0.7× 182 19.8k
Florin‐Andrei Taran Germany 23 18.6k 1.2× 8.9k 1.1× 6.6k 1.4× 6.8k 1.9× 1.6k 0.7× 77 26.3k
Christina B. Walter Germany 6 18.1k 1.2× 8.9k 1.1× 6.3k 1.3× 6.7k 1.9× 1.5k 0.6× 13 25.0k
Anne Berger France 37 11.3k 0.7× 7.5k 0.9× 3.5k 0.7× 3.5k 1.0× 3.2k 1.3× 148 17.7k
Grant A. McArthur Australia 74 15.0k 1.0× 3.8k 0.5× 5.4k 1.1× 15.2k 4.2× 1.5k 0.6× 395 26.8k

Countries citing papers authored by Janis M. Taube

Since Specialization
Citations

This map shows the geographic impact of Janis M. Taube's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janis M. Taube with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janis M. Taube more than expected).

Fields of papers citing papers by Janis M. Taube

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janis M. Taube. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janis M. Taube. The network helps show where Janis M. Taube may publish in the future.

Co-authorship network of co-authors of Janis M. Taube

This figure shows the co-authorship network connecting the top 25 collaborators of Janis M. Taube. A scholar is included among the top collaborators of Janis M. Taube based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janis M. Taube. Janis M. Taube is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Heymach, John V., David H. Harpole, Tetsuya Mitsudomi, et al.. (2023). Abstract CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. Cancer Research. 83(8_Supplement). CT005–CT005. 55 indexed citations
2.
Long, Georgina V., John M. Kirkwood, Christoph Höeller, et al.. (2023). Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).. Journal of Clinical Oncology. 41(16_suppl). 9504–9504. 8 indexed citations
3.
Giraldo, Nicolás A., Sneha Berry, Étienne Becht, et al.. (2021). Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery. Cancer Immunology Research. 9(11). 1262–1269. 6 indexed citations
4.
Ascierto, Paolo A., Carlo Bifulco, Fortunato Ciardiello, et al.. (2021). Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd, 2020, Italy). Journal of Translational Medicine. 19(1). 238–238. 3 indexed citations
5.
Finak, Greg, Leonard D’Amico, Nina Bhardwaj, et al.. (2021). New interpretable machine-learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy. Patterns. 2(12). 100372–100372. 21 indexed citations
6.
Lampert, Erika J., Alexandra S. Zimmer, Michelle R. Padget, et al.. (2020). Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. Clinical Cancer Research. 26(16). 4268–4279. 150 indexed citations
7.
Stein, Julie E., Evan J. Lipson, Tricia R. Cottrell, et al.. (2019). Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade. Clinical Cancer Research. 26(3). 545–551. 92 indexed citations
8.
Kim, Amy K., Faiz Gani, Andrew J. Layman, et al.. (2019). Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma. Cancer Immunology Research. 7(5). 805–812. 20 indexed citations
9.
Whelan, Sarah, Eran Ophir, Maya F. Kotturi, et al.. (2019). PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function. Cancer Immunology Research. 7(2). 257–268. 125 indexed citations
10.
Sunshine, Joel, Peter Nguyen, Genevieve J. Kaunitz, et al.. (2017). PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison. Clinical Cancer Research. 23(16). 4938–4944. 109 indexed citations
11.
Thompson, Elizabeth D., Marianna Zahurak, Adrian Murphy, et al.. (2016). Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. 66(5). 794–801. 359 indexed citations breakdown →
12.
Ascierto, Maria Libera, Tracee L. McMiller, Alan E. Berger, et al.. (2016). The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma. Cancer Immunology Research. 4(9). 726–733. 133 indexed citations
13.
Taube, Janis M., Geoffrey D. Young, Tracee L. McMiller, et al.. (2015). Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade. Clinical Cancer Research. 21(17). 3969–3976. 196 indexed citations
14.
Lastwika, Kristin J., Willie Wilson, Qing Kay Li, et al.. (2015). Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer. Cancer Research. 76(2). 227–238. 643 indexed citations breakdown →
15.
Jackson, Christopher M., Christina M. Kochel, Christopher J. Nirschl, et al.. (2015). Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination. Clinical Cancer Research. 22(5). 1161–1172. 54 indexed citations
16.
Llosa, Nicolás J., Michael Cruise, Ada Tam, et al.. (2014). The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints. Cancer Discovery. 5(1). 43–51. 1112 indexed citations breakdown →
17.
Rodić, Nemanja, Robert A. Anders, James R. Eshleman, et al.. (2014). PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation. Cancer Immunology Research. 3(2). 110–115. 42 indexed citations
18.
Taube, Janis M., Alison Klein, Julie R. Brahmer, et al.. (2014). Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy. Clinical Cancer Research. 20(19). 5064–5074. 1873 indexed citations breakdown →
19.
Lyford-Pike, Sofía, Shiwen Peng, Geoffrey D. Young, et al.. (2013). Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma. Cancer Research. 73(6). 1733–1741. 602 indexed citations breakdown →
20.
Cimino‐Mathews, Ashley, Andrea P. Subhawong, Hillary Elwood, et al.. (2012). Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas. Human Pathology. 44(6). 959–965. 122 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Timothy A. Chan Breakdown of academic impact, for papers by Sandra Demaria Breakdown of academic impact, for papers by Daniel S. Chen Breakdown of academic impact, for papers by Sarina A. Piha‐Paul Breakdown of academic impact, for papers by Omid Hamid Breakdown of academic impact, for papers by Haidong Dong Breakdown of academic impact, for papers by Florin‐Andrei Taran Breakdown of academic impact, for papers by Christina B. Walter Breakdown of academic impact, for papers by Anne Berger Breakdown of academic impact, for papers by Grant A. McArthur
Rankless by CCL
2026